FindTrial
Sign In

Oral COX-2 inhibitor Celecoxib in Peritoneal Dialysis Patients: effects on peritoneal transport and peritoneal defence.

Oral COX-2 inhibitor Celecoxib in Peritoneal Dialysis Patients: effects on peritoneal transport and peritoneal defence. - COXPD

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35652
Enrollment
16
Registered
2010-06-08
Start date
2010-06-01
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

giving Celecoxib

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: The patient must provide written consent prior to starting the study Patients must be over 18 years of age Patients must have CKD stage 5 and treatment with automated peritoneal dialysis; (APD) using a biocompatible PD fluid Not expected to receive a living donor transplant

Exclusion criteria

Exclusion criteria: Patients who do not meet the specific inclusion criteria. UF

Design outcomes

Primary

MeasureTime frame
Primary endpoint is amelioration of ultrafiltration after three months of treatment with Celecoxib.—

Secondary

MeasureTime frame
Secondary endpoints are differences in markers of inflammation(Ca125, Il-6, TNF, VEGF, hyaluronan, Il-1, Il-8 and MCP-1) and peritoneal transport (D/P creatinine, D/P urea, Kt/V) after three months of treatment with Celecoxib.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)